Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma by Roth, A. D. et al.
Annals of Oncology 11: 301-306, 2000.
© 2000 Kluwer Academic Publishers. Printed in the Netherlands.
Original article
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug
combination in gastric carcinoma
A. D. Roth,1 R. Maibach,2 G. Martinelli,3 N. Fazio,3 M. S. Aapro,3 O. Pagani,4 R. Morant,5
M. M. Borner,6 R. Herrmann,7 H. Honegger,8 F. Cavalli,4 P. Alberto,9 M. Castiglione2'6 &
A. Goldhirsch3'10 on behalf of the Swiss Group for Clinical Cancer Research (SAKK), Bern,
Switzerland and the European Institute of Oncology (EIO), Milan, Italy
'Oncosurgery, Department of Surgery, Hopital Cantonal Universitaire, Geneva; 2SIAK coordinating center, Bern, Switzerland; 3European Institute
of Oncology, Milan, Italy; ^Division of Oncology, Ospedale San Giovanni, Bellinzona; 5Division of Oncology, Department of Medicine C,
Kantonspital, St. Gallen; Institute of Medical Oncology, Inselspital, Bern; 1 Division of Oncology, Department of Medicine, Kantonspital, Basel;
^ Institute of Oncology and Haematology. Stadtspital Triemli, Zurich; 'Division of Oncology, Department of Medicine, Hopital Cantonal
Universitaire, Geneva; lcDivision of Oncology, Ospedale Civico, Lugano, Switzerland
Summary
Purpose; A multi-centric trial was performed to explore the
clinical activity, in terms of response and toxicity (primary
objectives), duration of response and survival (secondary
objectives), of docetaxel with cisplatin in advanced gastric
cancer (AGC).
Patients and methods: Patients with measurable unresect-
able and/or metastatic gastric carcinoma, performance status
^ 1, normal hematological, hepatic and renal functions and
not pretreated for advanced disease by chemotherapy received
up to eight cycles of TC (docetaxel 85 mg/m2 dl, cisplatin
75 mg/m2 dl) q3w. Dose escalation to 100 mg/m2 was per-
formed in five patients and was discontinued for excessive
toxicity.
Results: Forty-eight patients were accrued. A median of
5 cycles/patient was given. We observed 2 complete and 25
partial responses for an overall intent to treat response rate of
56% (95% CI: 41%-71%). Twelve patients had stable disease
for > 9 weeks (3 cycles). The median time to progression and
overall survival were 6.6 and 9 months, respectively. Grade ^ 3
toxicities were neutropenia 81%, anemia 32%, thrombocyto-
penia 4%, alopecia 36%, fatigue 9%, mucositis 9%, diarrhea
6%, nausea/vomiting 4%, neurologic 2%, and one anaphylaxis
precluding treatment administration. We recorded nine epi-
sodes of non-fatal febrile neutropenia in eight patients, two of
them with docetaxel at 100 mg/m2. There were no direct treat-
ment-related deaths.
Conclusions: TC is active in AGC with a high response rate
in a multicentric trial. Despite its hematotoxicity, this regimen
is well tolerated and can be recycled as originally planned in
78% of the cases. These results may serve as basis for further
developments of docetaxel containing regimens in this disease.
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Introduction
Despite a decline in its incidence, gastric carcinoma
remains one of the 10 leading causes of death by neoplasia
in the Western countries [1]. For a long period of time
gastric carcinoma was considered to be poorly chemo-
responsive. For instance, a combination of mitomycin C,
adriamycin and 5-fluorouracil (5-FU) (FAM) was used
with shortlived responses in 20%-40% of patients [2].
'Second generation' cytotoxic regimens such as
5-FU-cisplatin (FUP), 5-FU-adriamycin-methotrex-
ate (FAMTX), etoposide-adriamycin-cisplatin (EAP)
or etoposide-5-FU-leucovorin (ELF) were developed
in the late eighties and early nineties and were originally
shown to yield high response rates (RR) [3-6]. However,
results observed in subsequent randomized trials were
less convincing with response rates staying in the 20%-
25% range with a median time to progression not ex-
ceeding five months [7, 8].
Two recently proposed regimens seem more promis-
ing in gastric cancer. Epirubicin-cisplatin-5-FU in con-
tinuous infusion (ECF) was developed in the UK and is
based on a new administration modality of 5-FU. An
impressive response rate of 71% with 12% CR was
obtained in a phase II setting [9-11]. Compared with
FAMTX in a phase III randomized study, ECF yielded
a superior response rate (45% vs. 21%) and a superior
median time to progression (7.4 months versus 3.4
months). These data led the investigators to propose
ECF as standard practice [12]. An intensive weekly
chemotherapy called PELF (cisplatin, epirubicin, 5-FU
and leucovorin) was studied in Italy and reported to
yield a 62% response rate in a large phase II trial
enrolling 105 patients [13]. However, toxicity was sub-
stantial requiring regular use of colony stimulating fac-
tors. Although both regimens gave very encouraging
results and might deserve further development, they did
not incorporate new promising agents in this disease [14].
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Docetaxel, a semisynthetic taxoid developed in the
eighties, is derived from the needles of the European yew
tree, Taxus baccata [15]. Phase II studies showed that
docetaxel was active against a broad spectrum of human
solid tumors, among them ovarian, breast, gastric, head
and neck, and lung cancers [16-19]. Three phase II trials
in the United States, Europe and Japan, testing docetax-
el (60-100 mg/m2) as a single agent in advanced gastric
cancer, totaling 113 evaluable patients with measurable
disease yielded a response rate of 17%-24% [20-22].
These results prompted us to investigate docetaxel in
combination with other active agents in gastric carci-
noma. Cisplatin is widely used in gastric carcinoma in
combinations like ECF, FUP or PELF as discussed
above. In vitro studies with docetaxel have shown a lack
of cross resistance to cisplatin, etoposide and 5-FU [23].
Since the toxicity profiles of cisplatin and docetaxel
have little significant overlap, a combination of these
agents seemed to constitute a logical step of investiga-
tion. A phase I study testing the association of cisplatin
and docetaxel was conducted by the Rotterdam Cancer
Institute and showed that a dose of 85-100 mg/m2 of
docetaxel combined with 75 mg/m2 of cisplatin was
manageable and could be given for multiple courses [24].
Of note, among the 52 patients treated, 3 had gastric
cancer and 2 responded.
We report the results of a phase I—II trial investigating
the efficacy and the tolerability of the association of
docetaxel and cisplatin (TC) in metastatic gastric cancer
(SAKK 42/95) initiated in January 1996.
Patients and methods
Patients and treatment
Patients with metastatic or locally advanced adenocarcinoma of the
stomach not previously treated palliatively by systemic therapy and not
amenable to curative resection were enrolled in this study. The patients
were required to have a performance status < 1, normal blood counts,
creatinine clearance >60 ml/min, normal liver function tests, no
history of anaphylaxis and no peripheral neuropathy of any origin
greater than grade 1.
The treatment consisted in docetaxel 85 mg/m2 dl in a one hour i.v
infusion followed by cisplatin 75 mg/m2 dl in a one hour i.v. infusion
given every three weeks for up to eight cycles. If this dose was well
tolerated in the first cycle of the first six patients (no dose limiting
toxicity [DLT] defined as grade 4 hematological toxicity with infection
and/or grade 3 non-hematological toxicity except for alopecia and
nausea/vomiting), the dose of docetaxel was to be increased to 100
mg/m2 for subsequent patients in a phase I fashion. All patients
received a standard supportive regimen consisting of hyperhydration
(3 liters of normal saline or 5% dextrose/24 hours) during each course
of treatment and Fortecortine*' (dexamethasone) 8 mg p.o. adminis-
tered 12 and 6 hours before docetaxel infusion and 8 mg twice daily for
an additional 4 days. 5-HT3 inhibitors were used for emesis prophy-
laxis.
The next cycle of treatment could be postponed for no more than
two weeks to allow the resolution of toxicities. Patients were to be
removed from the study for any treatment delay longer than two
weeks. A 20% dose reduction of docetaxel was mandatory in case of
prolonged grade 4 neutropenia (> 7 days), grade 4 thrombocytopenia,
grade > 2 liver toxicity, grade > 3 diarrhea and grade 3 cutaneous
toxicity. A further 25% dose reduction was foreseen in the event that
the same type/grade toxicity was observed in subsequent cycles. If
grade 2 neurotoxicity was recorded the dose of docetaxel was to be
reduced by 20% along with a 25% reduction in cisplatin dose. The
study therapy was discontinued in the event of transitory grade > 2
renal toxicity or definitive decrease in renal function (creatinine clear-
ance <60 ml/min), grade 3 liver toxicity, grade > 3 neuropathy, grade
4 cutaneous toxicity, grade 3 anaphylactoid reaction and if a toxicity
recurred despite dose reductions.
Responses were assessed according to WHO criteria at the end of
every other cycle of treatment. The statistical analysis of the response
rate was by intention to treat. Patients not evaluable for response were
therefore kept in the denominator of the response rate. Complete or
partial responses had to be confirmed by a second evaluation per-
formed four or more weeks after the initial one. After completion of
eight cycles of treatment or discontinuation of chemotherapy, disease
status was reevaluated every three months. Toxicity was assessed
according to WHO grading for each cycle.
An 'optimal two-stage' design was chosen for this phase II trial
[25]. Such a design serves to build into the trial a safety measure
leading to early stopping in case the response rate is lower than
expected. Thirteen consecutive pts were enrolled in the first stage and
we recorded a sufficient number of responses to safely exclude that the
response rate was as low as 20%. This allowed us to proceed to the
second stage, in which an additional 35 cases were recruited up to a
total of 48
The trial was accepted by the ethical review boards of all partic-
ipating institutions. Every patient gave his or her written informed
consent.
Results
Forty-eight patients were enrolled in the study. Patient
characteristics are summarized in Table 1. There were 36
males and 12 females, whose performance status was 0
(48%) and 1 (52%). Forty-eight percent of the patients
had previously undergone a surgical resection of their
primary tumor (total or subtotal gastrectomy), and two
had received neoadjuvant or adjuvant chemotherapy. At
the time of study inclusion there was a median 4.5 kg
weight loss over the last three months. Of the 48 patients
enrolled 45 were fully evaluable for response. Two pa-
tients died early before the first response assessment
(one suicide and one pulmonary embolism) and one
patient had unmeasurable disease (protocol violation).
These three patients were kept in the final intent-to-treat
analysis of response.
The first six patients were given docetaxel 85 mg/m2
dl in one hour infusion followed by cisplatin 75 mg/m2
dl. Because of a good tolerance of TC at this dose level,
the docetaxel dose was then increased to 100 mg/m2.
However, we observed two febrile neutropenias and one
episode of grade 3 mucositis in the five patients enrolled
at this dose level. The trial was therefore carried on with
docetaxel at 85 mg/m2 thereafter. The five patients
treated with docetaxel at 100 mg/m2 were kept in the
final analysis.
Two complete (CR) and 25 partial responses (PR)
were recorded, giving a response rate (RR) of 56% (27
of 48 patients) (95% CI: 41%-71%) (Table 2). Twelve
patients had stable disease during at least three cycles of
treatment, four patients progressed immediately during
therapy and two went off treatment due to excessive
303
Table I. Patient characteristics.
Number of patients
Age (years)
Median
Range
Sex, n (%)
Male
Female
Performance status, n (%)
0
1
Appetite, n (%)
Good
Fair
None
Weight change in last three months (kg)
Median
Range
Previous surgery
Curative
Palliative
Previous adjuvant chemotherapy
Number of affected disease sites per patient
Median
Range
Patients with locally advanced disease only
Number of disease sites per patient (number of patients)
1
2
3
> 4
Disease sites (measurable and not measurable)
Lymph nodes
Stomach
Liver
Peritoneum
Lung
Bone
Ovary
Others
Table 2. Tumor response.
Overall best response Number of patients (total
CR 2 (4)
PR 25 (52)
SD (for > 3 cycles) 12(25)
PD* 6(12)
Early deaths 2 (4)
Non-measurable disease 1 (2)
48
55
27-75
36(75)
12 (25)
23 (48)
25 (52)
13(27)
28 (58)
7(15)
-4.5
-16-+5
23(48)
14
9
2(4)
3
1-5
7
6
14
17
11
36
33
16
15
9
9
3
12
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Figure 1. Overall survival for all patients.
* Including two patients who went off treatment due to toxicity.
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Figure 2. Time to progression for all patients.
toxicity. One patient had his primary resected after six
cycles of treatment. There is no significant difference in
response according to disease site. The RR in patients
with locoregional disease (stomach and regional lymph
nodes ± adjacent pancreas) was 44% (4 of 9), whereas
for patients with distant metastatic disease ± loco-
regional disease with no more than three disease sites or
more than three disease sites the RR were 59% (16 of 27)
and 58% (7 of 12), respectively. The median progression
free survival defined as the interval from start of the
treatment to disease progression or death in all patients
was 6.6 months (Figure 1). The median progression-free
survival in responders was 7.1 months. The median over-
all survival was 9 months (Figure 2). Thirty-nine pa-
tients had died at the time of the present evaluation.
Twenty-three patients received a second-line therapy
after disease progression or after failing TC. The regimens
the most frequently used were etoposide-leucovorin-
5-FU (ELF), 5-FU-adriamycine, 5-FU ± leucovorine,
epirubicin-mitomycin C-5-FU (EMF) or CPT11-
5-FU. Twelve patients received ^ 4 cycles and seven of
them ^ 6 cycles. Although this trial was not designed to
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Table 3 Hematoxicity. Table 4. Non-hematologic toxicity in percentage of 47 patients.
Toxicity
Leucocytes
Granulocytes
Thrombocytes
Anemia
Percentage of cycles
{n = 229)
Grade 3
21
25
0
Grade 4
4
31
1
Percentage of cycles
(n = 47)
Grade 3
40
24
0
21
Grade 4
11
57
4
11
Toxicity
Nausea/vomiting
Diarrhea
Mucositis
Fatigue
Alopecia
Neurological
Fluid retention*
Hypersensitivity reaction'
Grade 1
(%)
38
9
26
26
6
21
19
6
Grade 2
(%)
30
19
13
49
51
23
13
0
Grade 3
(%)
4
6
9
9
36
2
0
2
Grade 4
(%)
0
0
0
0
0
-
record responses to second line regimens, it can be
deduced from the number of cycles administred that a
good half of the patients treated in second line enjoyed
at least a stabilisation of their disease for several
months.
Treatment with TC was well tolerated. Two hundred
thirty cycles of treatment were administred with a
median of 5 cycles per patient. Seventy-nine percent of
the cycles were administered on schedule. The perfor-
mance status improved in 20%, 15%, 8% and 6% of the
patients during cycles 1, 2, 3 and 4, respectively, while
it remained stable in more than half of the patients.
During the same period the appetite stayed stable in
about half of the patients while it improved in 10% of
them. Seven patients died while on treatment. Four
patients died of progressive disease, two of pulmonary
embolism, and one committed suicide. The latter patient
suffered from Alzheimer's disease and developed grade
4 neurological disturbances consisting in disorientation
and depression during the first cycle of treatment. This
state of confusion was attributed by the treating physi-
cians to the concomitant medication with morphine and
dexamethasone, and not to the chemotherapy agents.
The toxicity analysis is based on 47 patients and 229
cycles of treatment. Cycle 1 of one patient was not
available due to early death on day 20 from pulmonary
embolism. Table 3 summarizes grade 3—4 hematological
toxicities per patient and per cycle. Despite the relatively
frequent occurrence of profound granulocytopenia, only
nine episodes of non fatal febrile neutropenia were seen
in eight patients (19% of the patients, 4% of the treat-
ment cycles). Two of the episodes of febrile neutropenia
occurred during the first cycle of treatment in the five
patients treated with docetaxel at 100 mg/m2. Other
main toxicities are reported per patient in Table 4 and
per cycle in Table 5. Grade 3—4 events were infrequent.
One patient presented with esophageal perforation of
unclear origin, another had one episode of upper GI
tract hemorrhage. Neither of these events appeared to be
related to the study chemotherapy. Two patients experi-
enced cutaneous reactions which could be attributed
to docetaxel. The first one had grade 1 erythema with
pruritus during the second cycle of treatment which
resolved spontaneously with moisturizing cream appli-
cation and never reoccurred. The second patient had
grade 3 diffuse xeroderma with erythrodermia and
pruritus of the sun exposed skin treated with topical
° Grades: 1 = mild, 2 = moderate, 3 = severe.
Table 5. Non-hematologic toxicity in percentage of 229 cycles of
treatment.
Toxicity
Nausea/vomiting
Diarrhea
Mucositis
Fatigue
Neurological
Fluid retention1
Hypersensitivity reaction"
Grade 1
29
5
13
40
14
9
2
Grade 2
12
5
4
21
8
4
0.4
Grade 3
1
2
2
2
0.4
0
0.4
Grade 4
0
0
0
0
0
-
-
° Grades. 1 = mild, 2 = moderate, 3 = severe.
steroids. This occurred during his fifth, and last cycle of
treatment.
Eight patients discontinued therapy due to toxicity.
One patient refused to continue the treatment because of
severe (grade 3) asthenia. One patient could not be
treated because of severe hypersensitivity reaction devel-
oped on two occasions despite adequate premedication.
One patient had prolonged thrombopenia precluding
further therapy. Because of very strict recommendations
for stopping therapy in case of grade 1 sustained renal
toxicity, five additional patients had their treatment
stopped after a median of 5 cycles. The protocol was
amended after the inclusion of the 30th patient. It was
recommended to give the cisplatin in a four-hour infu-
sion instead of one hour and a dose reduction scheme of
cisplatin in case of mild renal toxicity was proposed in
order to allow responding patients to receive further
treatment. Thereafter none of the 18 remaining patients
went off treatment due to renal toxicity.
Discussion
This trial shows that the association of cisplatin and
docetaxel (TC) is active in gastric carcinoma. It con-
firms the results of earlier phase I studies regarding the
feasibility of the regimen and its good tolerability.
With an intent to treat response rate of 56%, a
median time to progression of 6.6 months and a median
overall survival of 9 months observed in an international
multiinstitutional trial with 10 participating centers, TC
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can be considered as an active two drug combination in
gastric carcinoma with at least an additive effect be-
tween both drugs. This result could have been influenced
in part by recrutment selection since only patients with
a performance status < 1 were enrolled in the study.
However, it is common that patients enrolled in gastric
cancer trials have predominantly a good performance
status since otherwise their survival is poor [5, 8, 12, 26-
28]. The nonrandomized phase II design of this trial
does not allow any definitive conclusions nor any direct
comparison with other regimens. However, if we consid-
er data from other phase II or III trials, this two drug
regimen seems to be at least as good as second gener-
ation regimens in gastric cancer like EAP, FAMTX,
FUP or ELF [7, 8]. Our results are also very similar to
what can be expected from a more recent regimens like
ECF [12], or the more intensive and more toxic PELF
[13]. It is of interest to note that 37% of the responders
had met the partial response criteria after already two
cycles of treatment only (six weeks). The high response
rate as well as the rapidity of response observed make
TC a regimen highly suitable for neoadjuvant treatment,
where high efficacy over a short time period is expected.
Despite the reported hematological toxicity, TC was
well tolerated with a median of 5 cycles of treatment
given per patient and only nine episodes of non fatal
febrile neutropenia. The three fatalities recorded during
the treatment period (one suicide and two pulmonary
embolisms) do not seem to be directly and specifically
related to the treatment. This compares very favourably
with other regimens like EAP where fatalities were
reported or FAMTX where poor tolerance led to frequent
omission of dl5 methotrexate administration and to
reconsider the dosage of the original regimen [29-32],
TC is also certainly easier to prescribe and better toler-
ated than PELF, which is considered to be an intensive
regimen requiring growth factor support [13, 28]. Apart
from its hematotoxicity rate, which does not seem to
translate into an inacceptable number of febrile neutro-
penic episodes, TC is probably as well tolerated as ECF
and seems to give very similar results without the need
of an indwelling catheter and an external pump with its
risks and costs [33-35]. The renal problems observed
in five patients at the beginning of the trial did not
reappear after the change in cisplatin administration
time. In our experience the only adverse effect which
could preclude TC administration is anaphylaxis to the
docetaxel formula, an event observed in one patient
enrolled in this study.
Because the phase I study conducted by the Rotterdam
Cancer Institute recommended a dose of 85-100 mg/m2
of docetaxel combined with 75 mg/m2 of cisplatin, we
designed our trial with a dose escalation of docetaxel
from 85-100 mg/m2 and observed that docetaxel at the
latter dose in combination with cisplatin at 75 mg/m2
was too toxic according to our DLT criteria [24]. Other
more recent phase I reports confirm that this drug
combination is relatively toxic at this dose level. An
Australian group recommended to use it at 75/75 mg/m2
in lung cancer patients [36]. Others reported that this
combination at 100/75 mg/m2 was 'manageable' inspite
of 87% of short-lasting grade 3-4 leukopenia and
granulopenia leading to infections and neutropenic fever
in 10% and 4.5% of the courses, respectively [37]. In our
study where hematotoxicity was the DLT, dose escala-
tion of docetaxel with colony-stimulating factors sup-
port might seem to be the next logical step. However, the
peripheral neuropathy generated by this drug associa-
tion at a relatively low cumulative dose of both drugs
might impair its feasibility [38].
Another interesting aspect of TC is that it is a two
drug regimen which could be used as basis for the
development of potentially more potent docetaxel based
combinations incorporating three or more active drugs
in gastric cancer. Because of the observed toxicity, we
felt that a non hematotoxic drug would be most suitable
to be added to TC. The SAKK and EIO are presently
conducting a dose finding trial in advanced gastric
cancer adding 5-FU given in protracted continuous
infusion (p.c.i.) to the TC combination. Preliminary
data show that p.c.i. 5-FU can be added toTC without
decreasing the dose of docetaxel and cisplatin [39]. This
is one example of the several new generation regimens
incorporating docetaxel which may be developed on the
basis of our experience withTC in this tumor.
In conclusion, we show here that docetaxel in combi-
nation with cisplatin is a very potent regimen in gastric
cancer and is well tolerated.
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